Thursday, November 16, 2:30am - 4:00am (EST)
Your search did not return any results.
This Oral Abstract presentation will review results from the Phase 1 research into TBAJ-876, a new anti-TB compound being developed by TB Alliance. Abstract presentations will include "Antimycobacterial activity of a novel diarylquinoline (TBAJ-876) against diverse drug-susceptible and drug-resistant clinical isolates of M. tuberculosis," "Enhanced sterilising potential of regimens containing a novel diarylquinoline (TBAJ-876) in a preclinical mouse model of TB," and "Toxicological assessment of TBAJ-876, a second-generation diarylquinoline anti-tubercular drug, in rats and dogs".
Please see the online program for more information.
TB Alliance at the Union Conference